NCT04009941 2020-10-28
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
Peking University
Phase 4 Completed
Clinical Trials
7 trialsNCT02944604 2019-01-18
The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy
Peking University
Phase 4 Completed
NCT02953730 2016-11-03
The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents
ChineseAMS
Phase 4 Completed
NCT02805153 2016-06-20
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02805205 2016-06-20
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02805218 2016-06-20
PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02805166 2016-06-17
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed